A call to action: The need for hepatology‐focused educational interventions in Internal Medicine Residency training
Adam E. Mikolajczyk, Andrew A. Aronsohn, John F. McConville, Donald M. Jensen, Jeanne M. Farnan – 1 November 2014
Reply
Jeremie Guedj, Laetitia Canini, Scott Cotler, Harel Dahari – 31 October 2014
Effect of interferon‐alpha therapy on hepatitis D virus
Ashish Goyal, John M. Murray – 31 October 2014
Clinical frontiers in liver transplantation
John R. Lake – 29 October 2014
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
Willem Pieter Brouwer, Qing Xie, Milan J. Sonneveld, Ningping Zhang, Qin Zhang, Fehmi Tabak, Adrian Streinu‐Cercel, Ji‐Yao Wang, Ramazan Idilman, Hendrik W. Reesink, Mircea Diculescu, Krzysztof Simon, Mihai Voiculescu, Meral Akdogan, Wlodzimierz Mazur, Jurrien G.P. Reijnders, Elke Verhey, Bettina E. Hansen, Harry L.A. Janssen, for the ARES Study Group – 28 October 2014 – Entecavir (ETV) is a potent inhibitor of hepatitis B viral replication, but long‐term therapy may be required.
Soft and hard endpoints in acute variceal bleeding
Juan G. Abraldes, Puneeta Tandon – 28 October 2014
The continuum of hepatitis C testing and care
Kendra Viner, Danica Kuncio, E. Claire Newbern, Caroline C. Johnson – 28 October 2014 – A hepatitis C virus (HCV)‐infected person will ideally have access to quality health care and move through the HCV continuum of care (CoC) from HCV antibody (Ab) screening, HCV‐RNA confirmation, engagement and retention in medical care, and treatment. Unfortunately, studies show that many patients do not progress through this continuum. Because these studies may not be generalizable, we assessed the HCV CoC in Philadelphia from January 2010 to December 2013 at the population level.
Is Systemic heparinization necessary during living donor hepatectomy?
Joo Dong Kim, Dong Lak Choi, Young Seok Han – 28 October 2014 – Systemic heparinization has traditionally been performed during living donor hepatectomy (LDH) at most transplant centers because of the possibility of graft vascular thrombosis. However, no consensus on the use of systemic heparinization during LDH has yet emerged. The aims of the present study were to compare donor and recipient outcomes with reference to systemic heparinization and to determine whether or not systemic heparin needs to be administered to living donors.
IL‐30 (IL27p28) attenuates liver fibrosis through inducing NKG2D‐rae1 interaction between NKT and activated hepatic stellate cells in mice
Abhisek Mitra, Arun Satelli, Jun Yan, Xia Xueqing, Mihai Gagea, Christopher A. Hunter, Lopa Mishra, Shulin Li – 28 October 2014
Invasive aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases
Francesco Barchiesi, Susanna Mazzocato, Sara Mazzanti, Rosaria Gesuita, Edlira Skrami, Alessandro Fiorentini, Nina Singh – 28 October 2014 – Invasive aspergillosis (IA) in liver transplant recipients is associated with grave outcomes. We reviewed 116 individual cases reported in the literature from 1985 to 2013. IA was diagnosed after a median of 25 days after transplantation and involved a single organ in 51% of the cases, whereas in the remaining cases, multiple sites were involved.